公开(公告)号：US20160145262A1

公开(公告)日：2016-05-26

申请号：US14896706

申请日：2014-06-09

Applicant: BETTA PHARMACEUTICALS CO., LTD.

Inventor： Shaojing HU ,  Wei LONG ,  Fei WANG ,  Yinxiang WANG ,  Lieming DING

IPC: C07D491/056 ,  C30B29/54 ,  C30B7/14 ,  C30B7/00 ,  A61K31/519 ,  A61K45/06

CPC classification number: C07D491/056 ,  A61K31/519 ,  A61K45/06 ,  C07B2200/13 ,  C30B7/00 ,  C30B7/14 ,  C30B29/54

Abstract: Disclosed is Icotinib phosphate (i.e., the compound of Formula (I)) and polymorph forms thereof, and methods of preparing and using them.

Abstract translation: 公开了磷酸伊西替尼（即式（I）的化合物）及其多晶型形式，以及制备和使用它们的方法。

公开(公告)号：US20250154149A1

公开(公告)日：2025-05-15

申请号：US18839000

申请日：2023-02-14

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiaofeng XU ,  Xizhen SONG ,  Xintao ZHAO ,  Yan XU ,  Liang CHEN ,  Hongfei RONG ,  Zongquan LI ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC: C07D471/04 ,  A61K31/4985 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical composition comprising a compound as shown in formula I, and use of the pharmaceutical composition in treating diseases. The present invention also relates to a method for preparing the compound as shown in formula I.

公开(公告)号：US20250042853A1

公开(公告)日：2025-02-06

申请号：US18706666

申请日：2022-11-03

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Rongwen YANG ,  Yun SUN ,  Jian ZHANG ,  Xuegang YI ,  Teng MA ,  Yu WANG ,  Pingping WANG ,  Lieming DING ,  Hong LAN ,  Jiabing WANG

IPC: C07D209/22 ,  A61K31/403 ,  A61K31/407 ,  A61K31/437 ,  A61K31/4709 ,  C07D209/30 ,  C07D209/52 ,  C07D401/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/052

Abstract: The present invention relates to a compound as shown in formula (I). The present invention also provides a composition and preparation containing the compound, and a method for using and preparing the compound.

公开(公告)号：US20240352053A1

公开(公告)日：2024-10-24

申请号：US18683571

申请日：2022-08-19

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Liang CHEN ,  Changyong QIU ,  Xiangyong LIU ,  Jian TANG ,  Lieming DING ,  Jiabing WANG

IPC: C07F9/6558 ,  A61K31/675 ,  C07C55/10 ,  C07C57/15 ,  C07C59/245 ,  C07C59/255 ,  C07C309/04

CPC classification number: C07F9/65583 ,  A61K31/675 ,  C07C55/10 ,  C07C57/15 ,  C07C59/245 ,  C07C59/255 ,  C07C309/04 ,  C07B2200/13

Abstract: The present invention relates to salt and crystal form of an EGFR inhibitor, and a composition and the use thereof. The salt and crystal form of the EGFR inhibitor as represented by formula I of the present invention can be used for treating or preventing epidermal growth factor receptor-mediated diseases or medical conditions (such as L858R activation mutants, exon 19 deletion activation mutants, T790M resistance mutants and C797S resistant mutants) in certain mutant forms.

公开(公告)号：US20220402948A1

公开(公告)日：2022-12-22

申请号：US17763633

申请日：2020-09-25

Applicant: BETTA PHARMACEUTICALS CO., LTD.

Inventor： Xiangyong LIU ,  Changyong QIU ,  Haitong SHENG ,  Mengqiang LIU ,  Qichao SHEN ,  Guolong DU ,  Xiaodong SONG ,  Lieming DING ,  Jiabing WANG

IPC: C07F9/53

Abstract: The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20220119411A1

公开(公告)日：2022-04-21

申请号：US17259187

申请日：2019-07-12

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Bang FU ,  Yao ZHANG ,  Yiqian WANG ,  Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07D513/04 ,  C07D471/04 ,  C07D498/04 ,  C07D519/00 ,  C07D487/04 ,  C07D417/14

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20220098183A1

公开(公告)日：2022-03-31

申请号：US17427112

申请日：2020-01-20

Applicant: Betta Pharmaceuticals Co.,Ltd

Inventor： Yiqian WANG ,  Yao ZHANG ,  Bang FU ,  Jiabing WANG ,  Lieming DING

IPC: C07D413/14 ,  C07D487/04 ,  C07D471/10 ,  C07D495/10 ,  C07D487/08 ,  C07D451/02 ,  C07D491/107 ,  C07D498/04

Abstract: Provided herein are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20210300909A1

公开(公告)日：2021-09-30

申请号：US17261013

申请日：2019-07-19

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Yiqian WANG ,  Yao ZHANG ,  Bang FU ,  Jiabing WANG ,  Lieming DING

IPC: C07D413/06 ,  C07D263/57 ,  C07D401/04 ,  C07D401/06 ,  C07D413/14 ,  C07D417/06 ,  C07D277/66

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

公开(公告)号：US20240342169A1

公开(公告)日：2024-10-17

申请号：US18682227

申请日：2022-08-04

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Lijia LIU ,  Jing GUO ,  Yu WANG ,  Xiangdong ZHAO ,  Jie CHEN ,  Yang WANG ,  Xiaobin YUAN ,  Dong JI ,  Licheng KONG ,  Lieming DING

IPC: A61K31/501 ,  A61P35/00

CPC classification number: A61K31/501 ,  A61P35/00

Abstract: Embodiments of the present application provide Ensartinib or a salt thereof and a use of a composition containing Ensartinib or the salt thereof in treatment of a disease carrying MET 14 exon skipping mutation.

公开(公告)号：US20230391779A1

公开(公告)日：2023-12-07

申请号：US18021784

申请日：2021-08-17

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiaofeng XU ,  Jinheng GAO ,  Hongfei RONG ,  Xizhen SONG ,  Jie CHEN ,  Xiangyong LIU ,  Hongling SHEN ,  Jing GUO ,  Dan YAN ,  Hong LAN ,  Lieming DING ,  Jiabing WANG

IPC: C07D487/04 ,  C07D403/04 ,  C07D471/04 ,  C07D403/06 ,  C07D231/56 ,  C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D413/04 ,  C07D413/14 ,  C07D405/14 ,  C07D493/04 ,  C07C237/20 ,  C07D205/04 ,  A61P35/00

CPC classification number: C07D487/04 ,  A61P35/00 ,  C07D471/04 ,  C07D403/06 ,  C07D231/56 ,  C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D413/04 ,  C07D413/14 ,  C07D405/14 ,  C07D493/04 ,  C07C237/20 ,  C07D205/04 ,  C07D403/04

Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions comprising such compounds and use thereof. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer.